NCT05126537 is a clinical trial of no intervention in 28 Day Mortality, sponsored by Southeast University, China.

Who is sponsoring NCT05126537?

NCT05126537 is sponsored by Southeast University, China.

What drugs are being tested in NCT05126537?

Interventions in NCT05126537: no intervention.

What condition does NCT05126537 study?

NCT05126537 studies 28 Day Mortality.

Is NCT05126537 still recruiting?

NCT05126537 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT05126537

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis

Status unknown Last updated 30 November 2022

What this trial tests

trial testing no intervention in 28 Day Mortality in 100 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Southeast University, China
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

no intervention

Conditions studied

28 Day Mortality — all drugs for 28 Day Mortality →

Sponsor

Southeast University, China

Who can join

18 and older, any sex, with 28 Day Mortality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

there is high mortality rate of sepsis, 36% in 90-days of sepsis in China, and there is no effective treatment. Immunosuppression mediated by sepsis is an important cause of death in patients. Treg cells are important immunomodulatory cell. Treg's over-differentiation is involved in the development of sepsis induced immunosuppression. In sepsis patients, the expression of PD-1、CTLA-4 and TIGIT on Treg cell surface increased, and Treg cells with high expression of co-inhibitory molecules showed stronger immunosuppressive characteristics. MiR-155-5p is an unencoded RNA transcript from a proto-oncogene B cell integration cluster. In sepsis, the expression of miR-155 increased in peripheral blood and correlated with the patient's prognosis. Recent studies have shown that miR-155-5p promotes co-inhibitory molecules expressed on T cells in LCMV infected animal models. However, the relationship between the expression of peripheral blood miR-155-5p in sepsis patients and the expression of co-inhibitory molecules on Treg cell surface is not clear.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death.
Zheng LY, Duan Y, He PY, Wu MY, et al · · 2024 · cited 23× · PMID 38816685 · DOI 10.1186/s11658-024-00602-9

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting

Other Southeast University, China trials

Trials by the same sponsor.

NCT07519512 — Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients · NA · recruiting
NCT06990477 — Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability · NA · recruiting
NCT07362537 — Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS · NA · recruiting
NCT07327268 — Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS · not yet recruiting
NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05126537 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Southeast University, China
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing